FindTrial
Sign In

The Mechanistic Study of USP46 Regulating ENO1 Deubiquitination Modification to Mediate Glucose Metabolic Reprogramming and Promote Breast Cancer Progression.

The Mechanistic Study of USP46 Regulating ENO1 Deubiquitination Modification to Mediate Glucose Metabolic Reprogramming and Promote Breast Cancer Progression.

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105217
Enrollment
Unknown
Registered
2025-06-30
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Positive group and negative group.:None

Sponsors

Hangzhou Women's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Female patients diagnosed with breast cancer by pathology;

Exclusion criteria

Exclusion criteria: 1.Male breast cancer patients; 2. Patients with distant metastases; 3. Non-invasive breast cancer.

Design outcomes

Primary

MeasureTime frame
The positive rate of ENO1;—

Countries

China

Contacts

Public ContactFeng Fan

Hangzhou Women's Hospital

646303980@qq.com+86 135 8878 6855

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026